Correction to: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Co
- PDF / 529,649 Bytes
- 1 Pages / 595.276 x 790.866 pts Page_size
- 32 Downloads / 243 Views
CORRECTION
Correction to: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product Dietger Niederwieser1,2,3 · Caroline Hamm4 · Patrick Cobb5 · Mindy Mo6 · Cecily Forsyth7 · Alessandra Tucci8 · Vladimir Hanes6 · Vincent Delwail9 · Roman Hajek10 · David Chien6
© The Author(s) 2020
Correction to: Targeted Oncology (2020) 15:599–611 https://doi.org/10.1007/s11523-020-00748-4
Page 608, 4 Discussion, right column, second paragraph: The sentence, which previously read: “Equivalence in clinical efficacy of ABP 798 with respect to rituximab RP in patients with CD20-positive B cell NHL was further supported by the results of efficacy assessment at week 12, with a two-sided 90% CI (− 0.3 to 11.2%)”. should read:
The original article can be found online at https://doi.org/10.1007/ s11523-020-00748-4.
“Equivalence in clinical efficacy of ABP 798 with respect to rituximab RP in patients with CD20-positive B-cell NHL was further supported by the results of efficacy assessment at week 12, with a two-sided 90% CI (− 9.3 to 11.2%)”. The original article has been updated. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
* Dietger Niederwieser [email protected]‑leipzig.de 1
Division of Hematology and Oncology, University of Leipzig, Liebigstr. 19, 04106 Leipzig, Germany
2
Lithuanian University of Health Sciences, Kaunas, Lithuania
3
School of Medicine, Aichi Medical University, Nagakute, Aichi/Nagoya, Japan
4
Schulich School of Medicine, Western University, Windsor, ON, Canada
5
St. Vincent Frontier Cancer Center, Billings, MT, USA
6
Amgen Inc., Thousand Oaks, CA, USA
7
Gosford Hospital, Gosford, NSW, Australia
8
Hematology Department, ASST-Spedali Civili-Brescia, Brescia, Italy
9
Oncology‑Hematology and Cell Therapy, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
10
Department of Hematooncology, Faculty of Medicine, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic Vol.:(0123456789)
Data Loading...
